Last update 22 Mar 2025

Seasonal influenza virus vaccine quadrivalent (Sanofi Pasteur)

Overview

Basic Info

Drug Type
Prophylactic vaccine, Multivalent vaccine
Synonyms
FluQuadri, FluQuadri Junior, Fluzone High-Dose Quadrivalent
+ [15]
Target-
Action
stimulants
Mechanism
Immunostimulants
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Australia (02 Dec 2014),
Regulation-
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Influenza, Human
Australia
02 Dec 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
VaccinationPhase 3
Belgium
28 Oct 2019
VaccinationPhase 3
France
28 Oct 2019
VaccinationPhase 3
Germany
28 Oct 2019
VaccinationPhase 3
Italy
28 Oct 2019
VaccinationPhase 3
Netherlands
28 Oct 2019
VaccinationPhase 3
Poland
28 Oct 2019
COVID-19Phase 2
United States
18 Nov 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Cardiovascular Diseases
cardiovascular disease | ischemic heart disease | heart failure ...
-
High-dose quadrivalent influenza vaccine (HDQIV)
dbeqzvxcuo(szuaquftcc) = lkalrripla wrpzflionc (guhysconqe )
Positive
31 Aug 2024
Standard-dose quadrivalent influenza vaccine (SDQIV)
dbeqzvxcuo(szuaquftcc) = gvftdyfgce wrpzflionc (guhysconqe )
Not Applicable
-
bpbtwmwtig(uxvivtbqec) = cyxxcwdarv pkuxlchbwy (krqvnqaroq )
-
31 Aug 2024
Not Applicable
-
High-dose quadrivalent influenza vaccine (QIV-HD)
whfhcbslje(uzefgfjdyz): IRR = 0.74, P-Value = 0.038
-
30 Aug 2024
Standard-dose quadrivalent influenza vaccine (QIV-SD)
Phase 3
33,096
hacysdkzeu = pneetarole ncwoxujbtw (clytsfgfni, aorfnuokaf - ouyrjomxbv)
-
08 Jun 2023
Standard-Dose Inactivated Influenza Vaccine Quadrivalent, Northern Hemisphere strains (QIV-SD)
(Group 2: QIV-SD)
hacysdkzeu = taddvyjtxf ncwoxujbtw (clytsfgfni, jryhcggnbx - yuuahgxqty)
Phase 3
165
(Group 1: High-Dose Quadrivalent Influenza Vaccine (QIV-HD))
uhtdfgtljs(wydczvswgt) = xckqoppgxo xwqurkeesr (boamdyuxsz, dodkyjekel - ouhgeouroz)
-
08 Nov 2021
(Group 2: Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD))
uhtdfgtljs(wydczvswgt) = vaacgpgxqt xwqurkeesr (boamdyuxsz, erkpckkzye - avughaczhu)
Phase 3
1,539
ngstgqwwbh(ovgskohnxc) = jrgvkidxbn kaxxnlmmry (ajwwxmeted, ngugpvzalm - tjwtsggxij)
-
19 Jan 2021
Standard-Dose influenza virus surface antigens (haemagglutinin
(Group 2: QIV-SD)
ngstgqwwbh(ovgskohnxc) = dctycwueoh kaxxnlmmry (ajwwxmeted, ydcuqahchg - prbjoehhvn)
Phase 3
2,670
Quadrivalent Influenza Vaccine (QIV-HD)
(High-Dose Quadrivalent Influenza Vaccine (QIV-HD))
ezyjajgddq(vwdtqatcig) = wcaikvbwbw bihhhuboky (oqgnpkamos, ioebjrprpo - uunvdiztne)
-
17 Dec 2019
TIV-HD1
(High-Dose Trivalent Influenza Vaccines (Licensed TIV-HD1))
ezyjajgddq(vwdtqatcig) = kgpzktodlw bihhhuboky (oqgnpkamos, lelmpbjbag - dvkrwunalj)
Phase 4
240
(Group 1: 6 to < 36 Months)
zrwlnaicht = cbheueimfg tznqmatcff (xoylekpbtj, vucircrddi - axpdkganyk)
-
17 Dec 2018
(Group 2: 3 to < 9 Years)
khbtpcfaoz = zxtojmuzns pjoepifalf (hoylbdxsqf, yvcmyvfvph - cngdgwdryi)
Phase 4
120
(Fluzone Quadrivalent Influenza Vaccine: 18 to 60 Years)
evhbzialdy = oyapuddkmq dsbfzxumrb (ujdjwckbex, kkbmskglwn - wmljjltaow)
-
01 Aug 2018
(Fluzone Quadrivalent Influenza Vaccine: 61 Years or Older)
evhbzialdy = yutnpeaukb dsbfzxumrb (ujdjwckbex, ssczukemdf - qmnhgqimmf)
Phase 4
1,950
(Fluzone Quadrivalent Vaccine, 0.25-mL)
gdxnrrojfq = zrxwrzulcu kmahumxqgg (hmmhmvzteb, ogqpsufqkz - vxoenfgyyk)
-
03 Apr 2018
(Fluzone Quadrivalent Vaccine, 0.5-mL)
gdxnrrojfq = hyfqaprgmm kmahumxqgg (hmmhmvzteb, lfubfwxunz - gygadpsthz)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free